Golden
Atlas Venture

Atlas Venture

Atlas Venture creates and invests in biotech startup companies in the U.S. with seed and early stage venture investments.

Company Overview

Atlas Venture is a Cambridge, Massachusetts based early-stage, biotech-focused venture firm. Atlas seeks to invest in the technology and life sciences sectors with a focus on personalized medicine, medical technologies, therapeutics, biotechnology, biology, drug discovery technologies, therapeutic platforms, novel biopharmaceutical products, novel therapeutics, novel drug discovery platforms, therapeutic products, innovative biomedical technologies, diagnostics, and medical devices.

History

Atlas Venture is an early-stage venture capital firm that invests in life sciences startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts where the majority of its investments are located. Atlas rolled out its eleventh biotech fund totaling $350 million in June 2017, after closing its tenth fund in April 2015 with $280 million in commitments. The team is led by five investment partners: Kevin Bitterman, Bruce Booth, Jean-Francois Formela, David Grayzel, and Jason Rhodes.



Atlas has been investing in biotech since 1993, but the firm invested in both life sciences and IT until 2014, when it separated those businesses, with the Atlas Venture brand remaining associated with its biotech bets. The IT side became the seed-stage firm Accomplice.



Originally formed in 1980, Atlas historically invested in both life sciences and information technology startup companies. In October 2014, Atlas announced its shift to a biotech-only venture capital firm, with the technology-focused investment team forming a new firm, Accomplice, to continue investing in information technology startups.



Previously as a diversified firm, Atlas had raised over $3.0 billion of investor commitments across nine venture capital funds. The firm raised $705 million for its 2000-vintage fifth fund, $600 million for its 2001-vintage sixth fund, $385 million for its 2006-vintage seventh fund, $283 million for its 2009-vintage eighth fund, and $265 million for its 2013-vintage ninth fund.



At its largest, the firm held European offices in London, Paris, and Munich, and a West Coast office based in Seattle, Washington, in addition to the Boston-area headquarters. Today, the firm operates from a single office in Cambridge, Massachusetts.

Investments

Atlas Venture has made 492 investments. The firm has had 127 exits, including PillPack, Integral Ad Science, and Carbon Black. Atlas Venture has raised a total of $2.4B across 7 funds, one of them being Atlas Venture Opportunity Fund I. This fund was announced on Jan 2, 2019, and raised a total of $250M.

Investment approach

Atlas has invested in over 150 life sciences startups since it began investing in the sector in 1990. Atlas invests in a range of therapeutic areas, including immuno-oncology, autoimmunity/inflammation, neuroscience, gene/cell therapy and editing, and anti-infectives. The current portfolio includes gene/cell editing/therapy companies AVROBIO, Generation Bio, Intellia Therapeutics, Obsidian Therapeutics, and Unum Therapeutics; oncology companies Bicycle Therapeutics, Kyn Therapeutics, Replimune, Surface Oncology, and Unum Therapeutics; autoimmunity companies Nimbus Therapeutics and Padlock Therapeutics; anti-infectives company Spero Therapeutics; synthetic biology company Synlogic; RNA companies miRagen Therapeutics and Translate Bio; and CNS companies Cadent Therapeutics, Disarm Therapeutics, Navitor, and Rodin Therapeutics; and novel platform companies Accent Therapeutics, Kymera Therapeutics, Gemini Therapeutics, HotSpot Therapeutics, and Akero. Notable prior exits from Atlas’ life sciences portfolio include Actelion, Adnexus Therapeutics, Alnylam Pharmaceuticals, Annovation Biopharma, Annovation Biopharma, ArQule, Arrow Therapeutics, Arteaus Therapeutics, Avila Therapeutics, CoStim Pharmaceuticals, Crucell, deCODE genetics, Delinia, Exelixis, IFM Therapeutics Inc., Micromet, Momenta Pharmaceuticals, MorphoSys, Nimbus Apollo, Novexel, Padlock Therapeutics, Stromedix, and U3 Pharma.



  • Within technology, the firm focuses on payments, SMB, consumer-facing innovation, advances in biology, next-generation infrastructure, security, consumer services, small business infrastructure, fintech, emerging web service companies, next-generation media, gaming, and social technologies, enterprise and internet infrastructure, big data and mobile infrastructure, internet-related businesses and communications.
  • Within life sciences, it focuses on biopharmaceuticals.
  • It also invests in silicones, consumer discretionary, and internet and direct marketing retail, internet software and services, IT services, security software, memory chips, and broadband telecommunication services.



The firm prefers to invest in companies based in the Europe and United States with a focus on New England, Boston, Maine, Connecticut, New Hampshire, Rhode Island, Vermont, California, and San Francisco Bay Area. Its initial investment ranges from $0.25 million to $15 million per transaction. The firm prefers to be a lead investor and seeks board representation in its portfolio companies. Massachusetts.

Timeline

January 2, 2019

Atlas announce closing of $250m fund

Atlas Venture raised a $250m to support early stage biotech companies.

January 2, 2019

Atlas Venture Opportunity Fund I

$250M

June 29, 2017

Atlas Venture Fund XI, L.P.

$350M

June 2017

Atlas rolled out its eleventh biotech fund totaling $350 million in June 2017, after closing its tenth fund in April 2015 with $280 million in commitments.

April 17, 2015

Atlas Venture Fund X, L.P.

$280M

May 1, 2013

Atlas Venture Fund IX, L.P.

$265M

January 29, 2009

Atlas Venture Fund VIII, L.P.

$283M

February 1, 2006

Atlas Venture Fund VII

$385M

August 1, 2001

Atlas Venture Fund VI, L.P.

$600M

People

Name
Role
Related Golden topics

ADAM ROSENBERG

Advisor



Alex Harding

Associate



ANKIT MAHADEVIA

Advisor



BOB COPELAND

Advisor



Bruce Booth

Founder



Bruce Booth

Partner



CATHERINE STEHMAN-BREEN

Entrepreneur-in-Residence



Cecelia Joliat

Administrative Assistant



CYRUS MOZAYENI

Entrepreneur-in-Residence



David Grayzel

Partner



Diana Francis

Controller



DON NICHOLSON

Advisor



DOUG KERR

Advisor



GARY D. GLICK

Advisor



GEOFF MACKAY

Advisor



GEOFF MCDONOUGH

Advisor



GEORGE VLASUK

Advisor



GERHARD KOENIG

Entrepreneur-in-Residence



GERRALDINE (GERRY) HARRIMAN

Entrepreneur-in-Residence



HOWARD L. KAUFMAN

Advisor



Ian Owens

Executive Assistant



JASON GARDNER

Advisor



Jason Rhodes

Partner



Jean-François Formela

Partner



JEFFREY HATFIELD

Advisor



SHOW ALL (70)

Further reading

Title
Author
Link
Type
Date

5AM raises nearly $500M in two new biotech venture funds

Alaric DeArment

Web



As market shifts, Atlas Venture closes a $250 million fund to support its breakaway biotech bets

Connie Loizos

Web



Atlas Venture - Visnick & Caulfield



Web



Atlas Venture bags $250 million for its first opportunity fund - Healthcare Opportunity



Web



Atlas Venture Closes First Opportunity Fund, at $250M | FinSMEs



Web



Atlas Venture investor portfolio, rounds & team



Web



Atlas Venture Jobs, Employment | Indeed.com



Web



Atlas Venture Launches Generation Bio - EEI-BIOTECHFINANCES



Web



Atlas Venture raises $250m | Private Equity International



Web



Atlas Venture raises $250M for later-stage investments | FierceBiotech



Web



Atlas Venture raises $250M for Opportunity Fund

Alaric DeArment

Web



Atlas Venture Rounds Up $250 Million for Later-Stage Biotech Fund

Brian Gormley

Web



Biogen Idec, Atlas Venture Pump $17M into Ataxion



Web



Exclusive: Atlas Venture is splitting up

Dan Primack

Web



Is JPM Week worth it from a press perspective?

Arundhati Parmar

Web



Kevin Bitterman, Partner, Atlas Venture - Akero Therapeutics



Web



LifeSciVC | Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.



Web



Moving HQ to Boston, AtScale CEO Chris Lynch Talks VCs, Tech Scene



Web



Our Year In Review: Annual Talk On Macro, Biotech, and Atlas | LifeSciVC



Web



Predicting The Next Dominoes to Fall in 2019 | LifeSciVC



Web



See Ya Later, Techies: Atlas Venture Goes It Alone, Scoops Up $280M For Biotech

Luke Timmerman

Web



Startups Weekly: VCs celebrate the new year the only way they know how

Kate Clark

Web



SHOW ALL (30)

Documentaries, videos and podcasts

Title
Date
Link

Atlas Venture 2018 Year in Review B. Booth

Feb 11, 2019

Chris Lynch, Atlas Venture // Data Driven #28 // June 2014 (Hosted by FirstMark Capital)

Jun 26, 2014

Kinvey & Atlas Venture

Aug 28, 2012

Our Year In Review: Annual Talk On Macro, Biotech, and Atlas | LifeSciVC

February 12, 2019

Companies

Company
CEO
Location
Products/Services







Actelion







Adnxeus













Akrevia Therapeutics







Annovation Biopharma







ArQule







Arrow Therapeutics



















Avrobio



















CoStim Pharmaceuticals







Crucell













Delinia













Egalet Corporation







Exelixis







F-Star Alpha Limited



















Harbour Antibodies







SHOW ALL (53)

References